Capital Allocation When Everything Is Expensive

Imagine you are a CFO with $500 million in cash. Your board wants growth. Your CEO wants acquisitions. Your shareholders want returns. The problem? Every option on the table is expensive.

Public markets trade at 29x trailing earnings, nearly 80% above the historical mean of 16x. Private M&A targets demand 8 to 12x EBITDA across most sectors. Organic capex projects clear maybe 12% IRR on a good day. And buybacks at these valuations arguably destroy more value than they create.

This is the capital allocation problem that defines 2026. And most companies are getting it wrong.

The Trap of Relative Ranking

The conventional approach to capital allocation goes something like this: list all your options, rank them by expected return, and deploy capital starting from the top.

When multiples are reasonable, this framework works. You compare an acquisition at 6x EBITDA against organic growth at 15% ROIC against buybacks at a 7% earnings yield. The math is clean. The decisions are clear.

But when every option is expensive, relative ranking becomes dangerous. You end up picking the “least bad” option, which is just another way of saying you are overpaying for something because everything else is even more overpriced.

If your decision framework only works when multiples are reasonable, you do not have a framework. You have market timing disguised as strategy.

The Case for Absolute Hurdle Rates

Elite capital allocators do not rank options against each other. They set absolute return thresholds that every deployment must clear, regardless of what the rest of the market is doing.

Here is a practical framework used by leading treasury and corporate finance teams:

The M&A hurdle is intentionally 200 basis points higher than organic growth. Why? Because acquisitions carry integration risk, cultural risk, and execution risk that organic investments do not. The premium compensates for the additional uncertainty.

The buyback hurdle is simple but often ignored: if your stock’s earnings yield is below your cost of capital, buying it back is value-destructive by definition. At current S&P 500 valuations of 29x earnings, the earnings yield is roughly 3.4%. For most companies with a WACC of 8 to 10%, buybacks at today’s prices fail this test.

When Nothing Clears the Bar

Here is where most companies stumble. When no option clears the absolute hurdle rate, boards and management teams feel pressure to “do something” with the cash. Shareholder activists demand deployment. Analysts question whether management has a growth strategy.

But the data tells a different story.

Warren Buffett’s Berkshire Hathaway accumulated $340 billion in cash by 2025, up from $110 billion in 2018. Over those seven years, the S&P 500 PE expanded from roughly 20x to nearly 29x. Buffett did not panic. He did not chase expensive deals. He waited.

His words capture the philosophy perfectly: “The big money is not in the buying or the selling. It is in the waiting.”

This is not laziness or indecision. At current T-bill yields of approximately 5%, holding cash earns a guaranteed real return. For the first time in over a decade, patience is a compensated strategy.

What Leading Treasury Teams Do During Peak Multiples

The best corporate finance teams do not sit idle when they choose patience. They use the time strategically:

The Market Data Confirms This Approach

Consider the current landscape. The S&P 500 trailing PE ratio sits at 28.95, according to data from multpl.com as of March 2026. The historical mean is 16.20 and the median is 15.06. We are in rarefied territory.

On the M&A side, mid-market EBITDA multiples across key sectors tell a similar story. Manufacturing companies trade at 6 to 8x EBITDA. Financial services firms command 5 to 8x. SaaS businesses fetch 10 to 17x. Healthcare sits at 7 to 10x. These are averages from the First Page Sage 2025 EBITDA Multiples Report, and they reflect a market where sellers have pricing power.

For a company with a WACC of 9%, an acquisition at 10x EBITDA needs to generate post-synergy returns exceeding 14% (WACC + 500 bps) to clear the hurdle. At current multiples, very few deals meet that threshold without aggressive (and often unrealistic) synergy assumptions.

Patience as Strategy, Not Passivity

The distinction matters. Patience is not the absence of a capital allocation strategy. It is the highest-conviction expression of one.

When you hold cash because nothing meets your absolute return threshold, you are making three implicit bets:

1. Your hurdle rates are correctly calibrated to your cost of capital and risk tolerance.
2. Better opportunities will emerge as cycles turn (they always do).
3. The optionality value of dry powder exceeds the opportunity cost of not deploying.

All three of these bets are supported by decades of evidence. Companies that deploy capital disciplinedly through cycles outperform those that chase growth at any price.

The Bottom Line

The best capital allocators do not optimize for this quarter. They do not bow to pressure from activists who confuse activity with progress. They do not chase expensive acquisitions because “everyone else is doing deals.”

They set absolute hurdle rates. They apply them consistently. And when nothing clears the bar, they wait.

Sometimes the highest-return decision a CFO can make is choosing not to deploy capital at all.

That is not a failure of strategy. That is strategy working exactly as designed.

---

Sources: S&P 500 PE data from multpl.com (March 2026). Berkshire Hathaway cash holdings reported by Fortune and Rule One Investing (2025). EBITDA multiples from First Page Sage 2025 Report. T-bill yields approximate as of March 2026.